vesicle transport through interaction with t-SNAREs 1B pseudogene 2Genealiases: []
Q-omics provides the consensus-scored VTI1BP2 profile across patient tissues and cancer cell-line models. VTI1BP2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, VTI1BP2 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, VTI1BP2 RNA expression shows 15,624 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, COAD, and UVM as cancer lineages where VTI1BP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VTI1BP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VTI1BP2 survival associations across molecular data types. VTI1BP2 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VTI1BP2 RNA expression–survival associations across cancer types. High VTI1BP2 expression shows unfavorable associations in KICH, KIRC, LGG, LUSC, ACC and SKCM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for VTI1BP2 RNA expression.
This table summarizes VTI1BP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for VTI1BP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VTI1BP2 shows higher tumor expression in COAD, LUAD, LUSC, CHOL, KICH and STAD. The COAD box plot shows higher VTI1BP2 RNA expression in tumor versus normal tissue (log2 FC = +0.245, t-test p < 0.001).
This table shows molecular features associated with VTI1BP2 in patient tissues and cancer cell lines. In patient samples, VTI1BP2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
